

- 2 **Současné trendy v léčbě malobuněčného karcinomu plic**  
prof. MUDr. Miloš Pešek, CSc. Klinika pneumologie a ftizeologie FN, Plzeň
- 2 **Možná, pravděpodobná, nebo jistá idiopatická plicní fibróza?**  
MUDr. Martina Šterclová, Ph.D. | prof. MUDr. Martina Vašáková, Ph.D.  
Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 2 **Současnost a nové trendy v léčbě nemalobuněčného karcinomu plic**  
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol, Praha
- 3 **ACOS: překryvný syndrom CHOPN a astmatu**  
MUDr. Jaromír Zatloukal, Ph.D.  
Klinika plicních nemocí a tuberkulózy, FN a LF Univerzity Palackého, Olomouc
- 3 **Mepolizumab v léčbě těžkého astmatu**  
MUDr. Vratislav Sedlák, Ph.D. Plicní klinika LF UK a FN, Hradec Králové  
doc. MUDr. Milan Teřl, Ph.D. | MUDr. Olga Růžičková-Kirchnerová Pneumologická klinika LF UK a FN, Plzeň  
MUDr. Vladimír Koblížek, Ph.D. | MUDr. Ondřej Kudela | MUDr. Martin Blažek, Ph.D. Plicní klinika LF UK a FN, Hradec Králové
- 4 **Nízká incidence těžkých exacerbací asthma bronchiale při užívání fixní kombinace flutikason propionátu s formoterolem**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 4 **Nové fixní kombinace v léčbě chronické obstrukční plicní nemoci**  
MUDr. Viktor Kašák LERYMED, s. r. o., Oddělení respiračních nemocí, Praha
- 4 **Nové možnosti léčby CHOPN na podkladě deficitu  $\alpha$ 1-antitrypsinu**  
MUDr. Jan Chlumský, Ph.D. Pneumologická klinika 1.LF UK a Thomayerovy nemocnice, Praha
- 4 **Glukokortikoidy indukovaná osteoporóza u pacientů s CHOPN**  
MUDr. Olga Růžičková Revmatologický ústav, Praha
- 6 **Novinky v diagnostice a léčbě spánkové apnoe**  
MUDr. Milada Hobzová, Ph.D. Klinika plicních nemocí a tuberkulózy LF UP a FN, Olomouc
- 6 **Přístup k diagnostice teplot nejasného původu a „laterální myšlení“**  
MUDr. Luboš Kotík, CSc. I. interní oddělení, Fakultní Thomayerova nemocnice, Praha
- 6 **Dětská myopie na postupu**  
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

# Současné trendy v léčbě malobuněčného karcinomu plic

prof. MUDr. Miloš Pešek, CSc. Klinika pneumologie a ftizeologie FN, Plzeň

- 1 **Almquist, D.** – Mosalpuria, K. – Ganti, A. K.: Multimodality therapy for limited-stage small-cell lung cancer. *J Oncol Practice*, 2016, 12, s. 111–117.
- 2 **Corso, Ch. D.** – Rutter, Ch. E. – Park, H. S., et al.: Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer. *J Clin Oncol*, 2015, 33, s. 4240–4246.
- 3 **Fan, M.** – Zhang, J. – Liu, D., et al.: Comparison of PET/CT, 99mTc-MDP bone scan and serum alkaline phosphatase for detecting bony metastasis in patients with small cell lung cancer. *J Thorac Oncol*, 2015, 10, dopl. 2, S501, s. 7–16.
- 4 **Georgie, J.** – Lim, J. S. – Jang, J. S., et al.: Comprehensive genomic profiles of small cell lung cancer. *Nature*, 2015, 524, s. 47–53, doi: 10.1038/nature14664.
- 5 **Hanna, N.** – Bunn, P. A. – Langer, C., et al.: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. *J Clin Oncol*, 2006, 24, s. 2038–2043.
- 6 **Hermes, A.** – Bergman, B. – Bremnes, R., et al.: Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase III trial. *J Clin Oncol*, 2008, 26, s. 4261–4267.
- 7 **Ishii, H.** – Azuma, K. – Kawahara, A., et al.: Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. *J Thorac Oncol*, 2015, 10, s. 426–430.
- 8 **Kim, E. Y.** – Kim, Y. S. – Park, I., et al.: Prognostic significance of CT-determined sarcopenia in patients with small-cell lung cancer. *J Thorac Oncol*, 2015, 10, s. 1795–1799.
- 9 **Kolek, V.**, et al.: *Doporučené postupy v pneumologii*, 2013.
- 10 **Lara, P. N. Jr.** – Natale, R. – Crowley, J., et al.: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124. *J Clin Oncol*, 2009, 27, s. 2530–2535.
- 11 **Mandami, H.** – Indru, R. – Jalal, S. I.: Novel therapies in small cell lung cancer. (Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care.) *Transl Lung Cancer Res*, 2015, 4, s. 533–544.
- 12 **Nawal, L.** – Islam, K. M. M. – Deviany, P. E., et al.: Survival trends of small cell lung cancer (SCLC) in the United States: A SEER database analysis. *J Thorac Oncol*, 2015, 10, dopl. 2, S402, MINI37.12.
- 13 **Pillai, R. N.** – Owonikoko, T. K.: Small cell lung cancer: therapies and targets. *Semin Oncol*, 2014, 41, s. 133–142.
- 14 **Slotman, B.** – Faviere-Finn, C. – Interen, H. V., et al.: Which patients with ES-SCLC should receive thoracic radiotherapy (TRT) routinely? *J Thorac Oncol*, 2015, 10, S193, dopl. 2, ORAL10.03.
- 15 **Thomas, A.** – Szabo, E. – Pinsky, P.: Screening for small cell lung cancer: analysis of the national lung cancer screening trial data. *J Thorac Oncol*, 2015, 10, dopl. 2, S221, ORAL25.01.
- 16 **Vandeußen, A.** – Zaidi, A. H. – Martin, S. A., et al.: Peripheral limited small cell lung cancer (SCLC). Does surgical resection have a role in primary management? *J Thorac Oncol*, 2015, 10, dopl. 2, S499, P1.7–11.
- 17 **Videtic, G. M. M.** – Reddy, Ch. – Woody, N., et al.: Medically inoperable early stage small cell lung cancer: patterns of failure after SBRT. *J Thorac Oncol*, 2015, 10, dopl. 2, S626, P2.9–13.
- 18 **Wong, A. T.** – Rineer, J. – Schwarz, D., et al.: Assessing the impact of postoperative radiation therapy for completely resected limited-stage small cell lung cancer using the national cancer database. *J Thorac Oncol*, 2015, 11, s. 242–248.
- 19 **Xie, D.** – Marks, R. – Zhang, M., et al.: Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers. *J Thorac Oncol*, 2015, 10, s. 1213–1220.
- 20 **Yang, Ch. F. J.** – Chan, D. Y. – Speicher, P. J., et al.: Long-term survival after surgery for pathologic N1 and N2 small cell lung cancer: a comparison with nonoperative management. *J Thorac Oncol*, 2015, 10, dopl. 2, S193, ORAL10.06.
- 21 **Illei, P. B.** – Forde, P. – Hann, Ch., et al.: Expression in small cell lung carcinoma: an immunohistochemical analysis of 26 cases using two anti-PD-L1 antibodies. *J Thorac Oncol*, 2015, 10, dopl. 2, S360, MINI27.03.
- 22 **Ishii, H.** – Azuma, K. – Kawahara, A., et al.: Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. *J Thorac Oncol*, 2015, 10, s. 426–430.
- 23 **Karavasilis, V.** – Kotsakis, A. – Agelaki, S., et al.: Pazopanib as second line treatment of platinum sensitive SCLC patients: a multicenter phase II trial of the Hellenic Oncology Research Group. *J Thorac Oncol*, 2015, 10, dopl. 2, S401, MINI37.08.
- 24 **Mandami, H.** – Indru, R. – Jalal, S. I.: Novel therapies in small cell lung cancer. (Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care.) *Transl Lung Cancer Res*, 2015, 4, s. 533–544.
- 25 **Owonikoko, T. K.** – Csozsi, T. – Nackaerts, K., et al.: Alisertib (MLN8237)+paclitaxel versus placebo+paclitaxel for relapsed SCLC. *J Thorac Oncol*, 2015, 10, dopl. 2, S625, P2.9, s. 7–10.
- 26 **Rudin, Ch. M.** – Pietanza, M. C. – Spigel, D. R., et al.: A DLL3-targeted ADC, rovalpituzumab tesirine, demonstrates substantial activity in a phase I study in relapsed and refractory SCLC. *J Thorac Oncol*, 2015, 10, dopl. 2, S192, ORAL10.01.
- 27 **La Russa, F.** – Roca, E. – Grossi, F., et al.: Maintenance with lanreotide in SCLC patients, expressing somatostatin receptors, after response to first line therapy. *J Thorac Oncol*, 2015, 10, dopl. 2, S626, P2.7–11.

## Možná, pravděpodobná, nebo jistá idiopatická plicní fibróza?

MUDr. Martina Šterclová, Ph.D. | prof. MUDr. Martina Vašáková, Ph.D.

Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- 1 **Wells, A. U.**: The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF) – practical implications. *Respir Res*, 2013, 14, s. 52.
- 2 **Le Roupic, O.** – Bendaoud, S. – Chenivesse, C., et al.: Prognostic value of the initial chest high-resolution CT pattern in idiopathic pulmonary fibrosis. *Sarcoidosis Vasc Diffuse Lung Dis*, 2016, 32, s. 353–359.
- 3 **Walsh, S. L.** – Calandriello, L. – Sverzellati, N., et al.: UIP Observer Consortium. Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. *Thorax*, 2016, 71, s. 45–51.
- 4 **Yagihashi, K.** – Huckleberry, J. – Colby, T. V., et al.: Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia. *Eur Respir J*, 2016, 47, s. 1189–1197.
- 5 **Kaarteeaho, R.**: The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis. *Respir Res*, 2013, 14, s. 43.
- 6 **Aalokken, T. M.** – Naalsund, A. – Mynarek, G., et al.: Diagnostic accuracy of computed tomography and histopathology in the diagnosis of usual interstitial pneumonia. *Acta Radiol*, 2012, 53, s. 296–302.
- 7 **Huie, T. J.** – Brown, K. K.: Definitions of disease: should possible and probable idiopathic pulmonary fibrosis be enrolled in treatment trials? *Respir Investig*, 2015, 53, s. 88–92.
- 8 **Lee, J. W.** – Shehu, E. – Gjonbrataj, J., et al.: Clinical findings and outcomes in patients with possible usual interstitial pneumonia. *Respir Med*, 2015, 109, s. 510–516.
- 9 **Raghu, G.** – Lunch, D. – Godwin, J. D., et al.: Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. *Lancet Respir Med*, 2014, 2, s. 277–284.
- 10 **Yu, Y. F.** – Wu, N. – Chuang, Ch., et al.: Patterns and economic burden of hospitalizations and exacerbations among patients diagnosed with idiopathic pulmonary fibrosis. *J Manag Care Spec Pharm*, 2016, 22, s. 414–423.
- 11 **Richeldi, L.** – Cottin, V. – Flaherty, K. R., et al.: Design of the INPULSIS trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. *Respir Med*, 2014, 108, s. 1023–1030.
- 12 **Bonella, S.** – Stowasser, S. – Wollin, L.: Idiopathic pulmonary fibrosis: current treatment options and clinical appraisal of nintedanib. *Drug Design, Development and Therapy*, 2015, 9, s. 6407–6419.
- 13 **Richeldi, L.** – du Bois, R. M. – Praghu, G., et al.: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med*, 2014, 370, s. 2071–2082.

## Současnost a nové trendy v léčbě nemalobuněčného karcinomu plic

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol, Praha

- 1 **Travis, W. D.** – Brambilla, E. – Nicholson, A. G., et al.: The 2015 World Health Organization Classification of Lung Tumors. Impact of genetic, clinical and radiologic advances since the 2004 classification. *Journal of Thoracic Oncology*, 2015, 10, s. 1243–1260.
- 2 **Scagliotti, G. V.**, et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol*, 2008, 26, s. 3543–3551.
- 3 **Yang, J. C.**, et al.: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA study Phase II extension cohort. Abstrakt 943. Prezentováno na: 16<sup>th</sup> World Conference on Lung Cancer, 6.–9. 9. 2015, Denver, CO.
- 4 **Mitsudomi, T.**, et al.: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 Phase II study. Abstrakt 1406. Prezentováno na: 16<sup>th</sup> World Conference on Lung Cancer, 6.–9. 9. 2015, Denver, CO.
- 5 **Klak, E. L.** – Bang, Y. – Camidge, D. R., et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med*, 2010, 363, s. 1693–1703.
- 6 **Dong-Wan, K.**, et al.: Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. *J Clin Oncol*, 32, 2014, dopl., abstrakt 8003.
- 7 **Zilan, S.** – Meining, W. – Ao, Z.: Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance [J]. *Acta Pharmaceutica Sinica B*, 2015, 5, s. 34–37.
- 8 **Ajimizu, H.** – Kim, Y. H. – Mishima, M.: Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. *Med Oncol*, 2015, 32, s. 477.
- 9 **Thatcher, N.** – Hirsch, F. R. – Luft, A. V., et al.: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as

- first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. *The Lancet Oncology*, 2015, 16, s. 763–774.
- 10 Sander, A., et al.: Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. *NEJM*, 2006, 355, s. 2542–2550.
- 11 Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J. Y., et al.: LU-ME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. *Lancet Oncol*, 2014, 15, s. 143–155.
- 12 Garon, E. B., Ciuleanu, T. E., Arrieta, O., et al.: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. *Lancet*, 384, online, 2. 6. 2014, s. 665–673.
- 13 Takashi, S., Terufumi, K., Makoto, N., et al.: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. *Lancet Oncol*, 2014, 15, s. 1236–1244.
- 14 Spigel, D. R., et al.: A phase III study (CheckMate 017) of nivolumab (NIVO); anti-programmed death-1 (PD-1) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2015, 33, dopl., abstrakt 8009.
- 15 Paz-Ares, L., Horn, L., Borghaei, H., et al.: Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2015, 33, dopl., abstrakt LBA109.
- 16 Garon, E. B., Jizvi, N. A., Hui, R., et al.: KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*, 2015, 372, s. 2018–2028.
- 17 Herbst, R. S., Kim, D. W., Felip, E., et al.: KEYNOTE-010: Phase 2/3 Study of Pembrolizumab (MK-3475) vs Docetaxel for PD-L1-Positive NSCLC After Platinum-Based Therapy. Prezentováno na: ESMO Asia 2015 Congress, Singapur, 2015, s. 18–21.
- 18 Spira, A. I., et al.: Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). *J Clin Oncol*, 2015, 33, dopl., abstrakt 8010.
- 19 Brahmer, J., et al.: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*, 2015, 373, s. 123–135.

## ACOS: překryvný syndrom CHOPN a astmatu

MUDr. Jaromír Zatloukal, Ph.D.

Klinika plicních nemocí a tuberkulózy, FN a LF Univerzity Palackého, Olomouc

- 1 GINA, GOLD: *Asthma, COPD, and Asthma-COPD Overlap Syndrome*. dostupné z: [www.goldcopd.org](http://www.goldcopd.org).
- 2 Miravittles, M., et al.: Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD. *Arch Bronconeumol*, 2012, 48, s. 247–257.
- 3 Koblížek, V., et al.: Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. *Biomed Pap Med Fac. Univ Palacky Olomouc Czech Repub*, 2013, 157, s. 189–201.
- 4 Soriano, J. B., et al.: The proportional Venn diagram of obstructive lung disease. *Chest*, 2003, 124, s. 474–481.
- 5 Miravittles, M., et al.: Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. *Respiratory Medicine*, 2013, 107, s. 1053–1060.
- 6 Koblížek, V.: *Phenotypical heterogeneity of severe COPD subjects: Base-line results from the Czech multicentre research database of COPD*. ERS Congress, 2015.
- 7 Hardin, M., et al.: The clinical features of the overlap between COPD and asthma. *Respiratory Research*, 2011, 12, s. 127.
- 8 Orie, N. G. M., et al.: The host factor in bronchitis. In: Orie, N. G. M., et al.: *Bronchitis*. Assen, Nizozemsko, Royal Van Gorcum, 1961, s. 43–59.
- 9 Fletcher, C. M., et al.: The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. *BMJ*, 1959, 2, s. 257–266.

## Mepolizumab v léčbě těžkého astmatu

MUDr. Vratislav Sedlák, Ph.D. Plicní klinika LF UK a FN, Hradec Králové

doc. MUDr. Milan Teřl, Ph.D. | MUDr. Olga Růžičková-Kirchnerová

Pneumologická klinika LF UK a FN, Plzeň

MUDr. Vladimír Koblížek, Ph.D. | MUDr. Ondřej Kudela | MUDr. Martin Blažek, Ph.D.

Plicní klinika LF UK a FN, Hradec Králové

- 1 Teřl, M. – Pohunek, P.: *Strategie diagnostiky, prevence a léčby astmatu. Uvedení globální strategie do praxe v ČR*. Praha, Česká iniciativa pro astma, 2012.
- 2 Sedlák, V. – Chlumský, J. – Teřl, M. – Novotná, B., et al.: Doporučený postup pro diagnostiku a léčbu obtížně léčitelného astmatu v České republice. *Studia pneumologica et phthisiologica*, 2011, 71, s. 65–75.
- 3 Sedlák, V. – Kudela, O. – Koblížek, V.: *Problematické těžké astma bronchiale*. *ACTA MEDICINAE*, 2014, 3, s. 52–58.
- 4 Teřl, M., et al.: *Doporučený postup diagnostiky a léčby bronchiálního astmatu*. GEUM, Semily, 2015.
- 5 Sedlák, V. – Koblížek, V.: *Uřčování fenotypu astmatu ve výzkumu a klinické praxi*. *Medicina po promoci*, 2010.
- 6 Chung, K. F. – Godard, P. – Adelroth, E., et al.: Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. *Eur Respir J*, 1999, 13, s. 478–483.
- 7 Bel, E. H.: Clinical phenotypes of asthma. *Curr Opin Pulm Med*, 2004, 10, s. 44–50.
- 8 Good, T. J. J. – Kolakowski, Ch. A. – Groshong, S. D., et al.: Refractory asthma: Importance of bronchoscopy to identify phenotypes and direct therapy. *Chest*, 2012, 141, s. 599–606.
- 9 Moore, C. W. – Meyers, D. A. – Wenzel, S. E., et al.: Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *Am J Respir Crit Care Med*, 2010, 181, s. 315–323.
- 10 Hastie, A. T. – Moore, W. C. – Meyers, D. A., et al.: National Heart, Lung, and Blood Institute Severe Asthma Research Program Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. *J Allergy Clin Immunol*, 2010, 125, s. 1028–1036.
- 11 Haldar, P. – Pavord, I. D. – Shaw, D.: Cluster analysis and clinical asthma phenotypes. *Am J Respir Crit Care Med*, 2008, 178, s. 218–224.
- 12 Brusselle, G. – Vanderstichele, C. – Jordens, P., et al.: Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. *Thorax*, 2013, 68, s. 322–329.
- 13 Castro, M. – Rubin, A. S. – Laviolette, M., et al.: Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. *Am J Respir Crit Care Med*, 2010, 181, s. 116–124.
- 14 Ruzickova Kirchnerova, O. – Teřl, M.: Bronchial thermoplasty as an option for severe asthma patients—our experiences and retrospective evaluation. 2014, dostupné z: [http://erj.ersjournals.com/content/44/Suppl\\_58/P3735](http://erj.ersjournals.com/content/44/Suppl_58/P3735), vyhledáno 13. 4. 2016.
- 15 Berry, M. – Morgan, A. – Shaw, D., et al.: Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. *Thorax*, 2007, 62, s. 1043–1049.
- 16 Bousquet, J. – Chanez, P. – Lacoste, J. Y., et al.: Eosinophilic inflammation in asthma. *N Engl J Med*, 1990, 323, s. 1033–1039.
- 17 Menzella, F. – Lusuardi, M. – Galeone, C., et al.: Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases. *J Asthma Allergy*, 2015, 8, s. 105–114.
- 18 Wenzel, S. E. – Schwartz, L. B. – Langmack, E. L., et al.: Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. *Am J Respir Crit Care Med*, 1999, 160, s. 1001–1008.
- 19 Flood-Page, P. – Swenson, Ch. – Faiferman, I., et al.: A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. *Am J Respir Crit Care Med*, 2007, 176, s. 1062–1071.
- 20 Leckie, M. – ten Brinck, A. – Khan, J., et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet*, 2000, 356, s. 2144–2148.
- 21 Kips, J. – O'Connor, B. J. – Pauwels, R. A., et al.: Effect of SCH55700, a humanized anti-human interleukin-5 antibody in severe persistent asthma, a pilot study. *Am J Respir Crit Care Med*, 2003, 167, s. 1655–1659.
- 22 Pavord, I. D. – Howarth, P. – Bleeker, R. E., et al.: Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet*, 2012, 380, s. 651–660.
- 23 Prazma, C. – Wnezel, S. E. – Barnes, N., et al.: Characterization of an OCS-dependent severe asthma population treated with mepolizumab. *Thorax*, 2014, 69, s. 1141–1142.
- 24 Ortega, L. M. – Pavord, I. D. – Brusselle, G. G., et al.: Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med*, 2014, 371, s. 1198–207.

# Nízká incidence těžkých exacerbací asthma bronchiale při užívání fixní kombinace flutikason propionátu s formoterolem

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Papi, A. – Mansur, A. H. – Pertseva, T., et al.: Long-term fluticasone propionate/formoterol fumarate combination therapy is associated with a low incidence of severe asthma exacerbations. *J Aerosol Med Pulm Drug Deliv*, 2016, doi:10.1089/jamp.2015.1255.
- 2 Ducharme, F. M. – Ni, C. M. – Greenstone, I. – Lasserson, T. J.: Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. *Cochrane Database Syst Rev*, 2010, CD005535.
- 3 Lasserson, T. J. – Ferrarri, G. – Casali, L.: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. *Cochrane Database Syst Rev*, 2011, CD004106.
- 4 Chauhan, B. F. – Ducharme, F. M.: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. *Cochrane Database Syst Rev*, 2014, CD003137.

## Nové fixní kombinace v léčbě chronické obstrukční plicní nemoci

MUDr. Viktor Kašák LERYMED, s. r. o., Oddělení respiračních nemocí, Praha

- 1 Kašáková, E. – Kašák, V.: Může nesprávná inhalační technika ovlivnit efektivitu léčby pacientů s chronickou bronchiální obstrukcí? *Alergie*, 2015, 17, s. 39–44.
- 2 Teřl, M.: Inhalační léčba astmatu – cesta do průdušek i duše pacienta. *Alergie*, 2015, 17, s. 33–36.
- 3 Koblížek, V. – Chlumský, J. – Zindr, V., et al.: *Doporučený postup ČPFS pro diagnostiku a léčbu stabilní CHOPN*. Jessenius, Maxdorf, 2013.
- 4 Teřl, M. – Čáp, P. – Dvořáková, R., et al.: *Doporučený postup diagnostiky a léčby bronchiálního astmatu*. ČPFS, ČSAKI, GEUM, 2015.
- 5 *Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease*. Aktualizováno 2016. GOLD 2016; dostupné z: [www.goldcopd.com](http://www.goldcopd.com).
- 6 *Global strategy for asthma management and prevention*. Revidováno 2016. GINA 2016; dostupné z: [www.ginasthma.org](http://www.ginasthma.org).
- 7 Kašák, V.: Farmakoterapie CHOPN v r. 2015. *Postgraduální medicína*, 2015, 17, příloha č. 1, s. 6–22.
- 8 Cazzola, M. – Page, C. P. – Calzeta, L., et al.: Pharmacology and therapeutics of bronchodilators. *Pharmacol Rev*, 2012, 64, s. 450–504.
- 9 Barjaktarevic, I. Z. – Arrendondo, A. F. – Cooper, C. B.: Positioning new pharmacotherapies for COPD. *Int J COPD*, 2015, 10, s. 1427–1442.
- 10 Kašák, V.: Indakaterol/glykopyrronium bromid – první fixní kombinace s dlouhodobým duálním bronchodilatačním účinkem. *Farmakoterapie*, 2014, 10, s. 436–447.
- 11 Kudela, O. – Sedlák, V. – Koblížek, V.: Duální bronchodilatační léčba. *ACTA MEDICINAE*, 2015, 10, s. 44–46.
- 12 Marek, M.: Nová duální kombinace acilidinium bromidu a formoterolu v léčbě nemocných s chronickou obstrukční plicní nemocí. *Farmakoterapie*, 2015, 11, s. 492–503.
- 13 Barnes, P. J.: Scientific rationale for inhaled combination therapy with long-acting  $\beta_2$ -agonists and corticosteroids. *Eur Respir J*, 2002, 19, s. 182–189.
- 14 Bateman, E. D. – Mahler, D. A. – Vogelmeier, C. F., et al.: Recent advances in COPD disease management with fix dose long-acting combination therapies. *Expert Rev Respir Med*, 2014, 8, s. 357–379.
- 15 Marek, M.: Nová léková kombinace Relvar Ellipta pro nemocné s CHOPN a s bronchiálním astmatem. *Stud Pneumol Phtiseol*, 2014, 6, s. 194–200.

## Nové možnosti léčby CHOPN na podkladě deficitu $\alpha$ 1-antitrypsinu

MUDr. Jan Chlumský, Ph.D. Pneumologická klinika 1.LF UK a Thomayerovy nemocnice, Praha

- 1 Campos, M. A. – Lascano, J.: Current best practice in testing and augmentation therapy. *Ther Adv Respir Dis*, 2014, 8, s. 150–161.
- 2 Chapman, K. R. – Burdon, J. G. W. – Piitulainen, E., et al.: Intravenous augmentation treatment and lung density in severe  $\alpha$ 1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. *Lancet*, 2015, 386, s. 360–368, [http://doi.org/10.1016/S0140-6736\(15\)60860-1](http://doi.org/10.1016/S0140-6736(15)60860-1).
- 3 Kelly, E. – Greene, C. M. – Carroll, T. P., et al.: Alpha-1 antitrypsin deficiency. *Respiratory Medicine*, 2010, 104, s. 763–772, <http://doi.org/10.1016/j.rmed.2010.01.016>.
- 4 McElvaney, N. G. – Teschler, H. – Stockley, R., et al.: Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. *Respiratory Medicine*, 2009, 34, s. 1, <http://doi.org/10.1186/1750-1172-8-149>.
- 5 Stockley, R. – Parr, D. G. – Piitulainen, E., et al.: Therapeutic efficacy of  $\alpha$ 1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. *Respiratory Research*, 2010, 11, s. 136, <http://doi.org/10.1186/1465-9921-11-136>.
- 6 Stockley, R. A. – Miravittles, M. – Vogelmeier, C.: Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. *Orphanet Journal of Rare Diseases*, 2013, 8, s. 1, <http://doi.org/10.1186/1750-1172-8-149>.
- 7 Stoller, J. K. – Aboussouan, L. S.: A review of  $\alpha$ -1 antitrypsin deficiency. *American Journal of Respiratory and Critical Care Medicine*, 2012, 185, s. 246–259, <http://doi.org/10.1164/rccm.201108-1428CI>.
- 8 Stoller, J. K.: American Thoracic Society/European Respiratory Society Statement. *American Journal of Respiratory and Critical Care Medicine*, 2003, 168, s. 818–900, <http://doi.org/10.1164/rccm.168.7.818>.

## Glukokortikoidy indukovaná osteoporóza u pacientů s CHOPN

MUDr. Olga Růžičková Revmatologický ústav, Praha

- 1 Kanis, J. A. – Johansson, H. – Oden, A., et al.: A meta-analysis of prior corticosteroid use and fracture risk. *J Bone Miner Res*, 2004, 19, s. 893–899.
- 2 Lekamwasam, S. – Adachi, J. D. – Agnusdei, D., et al.: A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporos Int*, 2012, 23, s. 2257–2276.
- 3 Adachi, J. D. – Ioannidis, G.: Calcium and vitamin D therapy in corticosteroid-induced bone loss: What is the evidence? *Calcif Tissue Int*, 1999, 65, s. 332–336.
- 4 de Vries, F. – Bradle, M. – Leufkens, H. G., et al.: Fracture risk with intermittent high dose oral glucocorticoid therapy. *Arthritis Rheum*, 2007, 56, s. 208–214.
- 5 Adachi, J. D. – Papaioannou, A.: In whom and how to prevent glucocorticoid-induced osteoporosis. *Best Pract Res Clin Rheumatol*, 2005, 19, s. 1039–1064.
- 6 Adachi, J. D. – Saag, K. G. – Delmas, P. D., et al.: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. *Arthritis Rheum*, 2001, 44, s. 202–211.
- 7 Bianchi, M. L.: Glucocorticoids and bone: some general remarks and some special observations in pediatric patients. *Calcif Tissue Int*, 2002, 70, s. 384–390.
- 8 Canalis, E. – Mazzotti, G. – Gustina, A., et al.: Glucocorticoid-induced osteoporosis: pathophysiology and therapy. *Osteoporos Int*, 2007, 18, s. 1319–1328.
- 9 Cohen, S. – Levy, R. M. – Keller, M., et al.: Risedronate therapy prevents corticosteroid-induced bone loss. *American College of Rheumatology, Arthritis&Rheumatism*, 1999, 42, s. 2309–2318.
- 10 Etmann, M. – Sadatsafavi, M. – Ganjizadeh Zavareh, S., et al.: Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis. *Drug Saf*, 2008, 31, s. 409–414.
- 11 Rizzoli, R. – von Tscharner, V. – Fleisch, H.: Increase of adenylate cyclase catalytic-unit activity by dexamethasone in rat osteoblast-like cells. *Biochem J*, 1986, 237, s. 447–454.
- 12 Leib, E. S. – Saag, K. G. – Adachi, J. D., et al.: Official positions for FRAX clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis



- Foundation on FRAX. *J Clin Densitom*, 2011, 14, s. 212–219.
- 13 Cohen, S. B. – Dore, R. K. – Lane, N. E., et al.: Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. *Arthritis Rheum*, 2008, 58, s. 1299–1309.
  - 14 Compston, J. – Reid, D. M. – Boisdron, J., et al.: Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. *Osteoporos Int*, 2008, 19, s. 1247–1250.
  - 15 Canalis, E. – Mazziotti, G. – Gustina, A., et al.: Glucocorticoid-induced osteoporosis: pathophysiology and therapy. *Osteoporos Int*, 2007, 18, s. 1319–1328.
  - 16 Einstein, R. S. – Jilka, R. L. – Partity, A. M., et al.: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. *J Clin Invest*, 1998, 102, s. 274–282.
  - 17 Einstein, R. S.: Glucocorticoid-induced osteoporosis. In: *MR ASB (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism*. John Wiley & Sons, Hoboken, NJ, 2009, doi:10.1002/9780470623992.ch 58.
  - 18 Rochefort, G. Y. – Pallu, S. – Benhamou, C. L.: Osteocyte: the unrecognized side of bone tissue. *Osteoporos Int*, 2010, 21, s. 1457–1469.
  - 19 Den Uyl, D. – Bultink, I. E. – Lems, W. F.: Advances in glucocorticoid-induced osteoporosis. *Curr Rheumatol Rep*, 2011, 13, s. 233–240.
  - 20 Hayashi, K. – Yamaguchi, T. – Yano, S., et al.: BMPAVnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. *Biochem Biophys Res Commun*, 2009, 379, s. 261–266.
  - 21 Yao, W. – Cheby, Z. – Busse, C., et al.: Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. *Arthritis Rheum*, 2008, 58, s. 1674–1686.
  - 22 Hayashi, K. – Yamaguchi, T. – Yano, S., et al.: BMPAVnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. *Biochem Biophys Res Commun*, 2009, 379, s. 261–266.
  - 23 Yao, W. – Cheby, Z. – Busse, C., et al.: Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. *Arthritis Rheum*, 2008, 58, s. 1674–1686.
  - 24 Vestergaard, P. – Rejnmark, L. – Mosekilde, L.: Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. *Calcif Tissue Int*, 2008, 82, s. 249–257.
  - 25 Cooper, M. S. – Rabbitt, E. H. – Goddard, P. E., et al.: Osteoblastic 11 beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. *J Bone Miner Res*, 2002, 17, s. 979–986.
  - 26 Stěpán, J.: Osteoporóza a metabolická onemocnění skeletu. In: Pavelka, K., et al.: *Revmatologie*. Praha, Maxdorf Jessenius, 2012, s. 483–552.
  - 27 Grossmann, J. M. – Gordon, R. – Ranganath, V. K., et al.: American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Care Res (Hoboken)*, 2010, 62, s. 1515–1526.
  - 28 Hahn, T. J. – Hahn, B. H.: Osteopenia in subjects with rheumatic diseases: Principles of diagnosis and therapy. *Semin Arthritis Rheum*, 1976, 6, s. 65–88.
  - 29 Hahn, T. J. – Halstead, L. R. – Teitelbaum, S. L., et al.: Altered mineral metabolism in glucocorticoid-induced osteopenia: Effect of 25-hydroxyvitamin D administration. *J Clin Invest*, 1979, 64, s. 655–665.
  - 30 Kanis, J. A. – Johansson, H. – Oden, A., et al.: Guidance for the adjustment of FRAX according to the dose of glucocorticoids. *Osteoporos Int*, 2011, 22, s. 809–816.
  - 31 Hayashi, K. – Yamaguchi, T. – Yano, S., et al.: BMPAVnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. *Biochem Biophys Res Commun*, 2009, 379, s. 261–266.
  - 32 Hofbauer, L. C. – Rauner, M.: Live and let die: molecular effects of glucocorticoids on bone cells. *Mol Endocrinol*, 2009, 23, s. 1525–1531.
  - 33 Grossmann, J. M. – Gordon, R. – Ranganath, V. K., et al.: American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Care Res (Hoboken)*, 2010, 62, s. 1515–1526.
  - 34 Lekawam, S. – Adachi, J. D. – Agnusdei, D., et al.: for the Joint IOF-ECTS GIO Guidelines Working Group: A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporos Int*, 2012, doi: 10.1007/s00198-012-1958-1.
  - 35 Hoibauer, L. C. – Gori, F. – Riggs, B. L., et al.: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. *Endocrinology*, 1999, 140, s. 4382–4389.
  - 36 Hoibauer, L. C. – Zeitz, U. – Schoppert, M., et al.: Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. *Arthritis Rheum*, 2009, 60, s. 1427–1437.
  - 37 Makovic, V. – Heaney, R. P.: Calcium balance during human growth: Evidence for threshold behavior. *Am J Clin Nutr*, 1992, 55, s. 992–996.
  - 38 Dawson-Hughes, B. – Dallas, G. E. – Krall, E. A., et al.: A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. *N Engl J Med*, 1990, 323, s. 878–883.
  - 39 Hahn, T. J. – Hahn, B. H.: Osteopenia in subjects with rheumatic diseases: Principles of diagnosis and therapy. *Semin Arthritis Rheum*, 1976, 6, s. 65–88.
  - 40 Hahn, T. J. – Halstead, L. R. – Teitelbaum, S. L., et al.: Altered mineral metabolism in glucocorticoid-induced osteopenia: Effect of 25-hydroxyvitamin D administration. *J Clin Invest*, 1979, 64, s. 655–665.
  - 41 Lane, N. E. – Genant, H. K. – Kiney, J. H., et al.: Effect of intermittent cyclic etidronate (ICT) therapy for glucocorticoid-induced osteoporosis in rheumatoid arthritis: Interim analysis. *J Bone Miner Res*, 1993, 8, s. 5262.
  - 42 Pitt, P. – Li, F. – MacIntosh, C.: A double-blind placebo-controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term corticosteroid treatment. *J Bone Miner Res*, 1997, 12, s. 5510.
  - 43 Poubelle, P. E. – Adachi, J. D. – Hawkins, F.: Alendronate increases bone mineral density in patients on glucocorticoid therapy: Results of the multinational study. *Arthritis Rheum*, 1997, 40, s. 5327.
  - 44 Lund, B. – Andersen, R. B. – Trios, T., et al.: OH: Effect of 1-alpha-hydroxy vitamin D3 and 1,25-dihydroxy vitamin D3 on intestine and bone in glucocorticoid-treated patients. *Clin Endocrinol*, 1977, 7, s. 177–181.
  - 45 Ringe, J. D.: Active vitamin D metabolites in glucocorticoid-induced osteoporosis. *Calcif Tissue Int*, 1997, 60, s. 124–127.
  - 46 Adachi, J. D. – Ioannidis, G.: Calcium and vitamin D therapy in corticosteroid-induced bone loss: What is the evidence? *Calcif Tissue Int*, 1999, 65, s. 332–336.
  - 47 Ringe, J. D. – Faber, H.: Calcium and vitamin D in the prevention and treatment of glucocorticoid-induced osteoporosis. *Clin Exp Rheumatol*, 2000, 18 (dopl. 21), s. 44–48.
  - 48 Laan, R. F. – van Riel, P. L. – van de Putte, L. B., et al.: Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. *Ann Intern Med*, 1993, 119, s. 963–968.
  - 49 Lane, N. E. – Genant, H. K. – Kiney, J. H., et al.: Effect of intermittent cyclic etidronate (ICT) therapy for glucocorticoid-induced osteoporosis in rheumatoid arthritis (RA): Interim analysis. *J Bone Miner Res*, 1993, 8 (dopl.), s. 262.
  - 50 Langdahl, B. L. – Marin, F. – Shane, E., et al.: Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. *Osteoporos Int*, 2009, 20, s. 2095–2104.
  - 51 Leib, E. S. – Saag, K. G. – Adachi, J. D., et al.: Official positions for FRAX clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX. *J Clin Densitom*, 2011, 14, s. 212–219.
  - 52 Lekawam, S. – Adachi, J. D. – Agnusdei, D., et al.: for the Joint IOF-ECTS GIO Guidelines Working Group: A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporos Int*, 2012, doi: 10.1007/s00198-012-1958-1.
  - 53 Lund, B. – Andersen, R. B. – Trios, T., et al.: Effect of 1-alpha-hydroxy vitamin D3 and 1,25-dihydroxy vitamin D3 on intestine and bone in glucocorticoid-treated patients. *Clin Endocrinol*, 1977, 7, s. 177–181.
  - 54 Marenzana, M. – Greenslade, K. – Eddleston, A., et al.: Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. *Arthritis Rheum*, 2011, 63, s. 2385–2395.
  - 55 Marini, J. C.: Do bisphosphonates make children's bones better or brittle? *N Engl J Med*, 2003, 349, s. 423–426.
  - 56 Makovic, V. – Heaney, R. P.: Calcium balance during human growth: Evidence for threshold behavior. *Am J Clin Nutr*, 1992, 55, s. 992–996.
  - 57 Mok, C. C. – Ying, K. Y. – To, C. H., et al.: Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. *Ann Rheum Dis*, 2011, 70, s. 778–784.
  - 58 Neer, R. M. – Arnaut, C. D. – Zanchetta, J. R., et al.: Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med*, 2001, 344, s. 1434–1441.
  - 59 Okada, Y. – Nawata, M. – Nakayama, S., et al.: Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. *J Rheumatol*, 2008, 35, s. 2249–2254.
  - 60 Pitt, P. – Li, F. – Macitohs, C.: A double-blind placebo-controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term corticosteroid treatment. *J Bone Miner Res*, 1997, 12 (dopl.), s. 510.
  - 61 Pitt, P. – Li, F. – Todd, P., et al.: A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment. *Thorax*, 1998, 53, s. 351–356.
  - 62 Poubelle, P. E. – Adachi, J. D. – Hawkins, F.: Alendronate increases bone mineral density in patients on glucocorticoid therapy: Results of the multinational study. *Arthritis Rheum*, 1997, 40 (dopl.), s. 327.
  - 63 Rauch, A. – Gossyve, V. – Bradle, D., et al.: An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. *FASEB J*, 2011, 25, s. 1323–1332.
  - 64 Reid, D. M. – Devogelaer, J. P. – Saag, K., et al.: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. 2009, 373, s. 1253–1263, doi: http://dx.doi.org/10.1016/S0140-6736(09)62050-6.
  - 65 Ringe, J. D. – Faber, H.: Calcium and vitamin D in the prevention and treatment of glucocorticoid-induced osteoporosis. *Clin Exp Rheumatol*, 2000, 18 (dopl. 21), s. 44–48.
  - 66 Ringe, J. D.: Active vitamin D metabolites in glucocorticoid-induced osteoporosis. *Calcif Tissue Int*, 1996, 237, s. 124–127.
  - 67 Rizzoli, R. – Adachi, J. D. – Cooper, C., et al.: Management of Glucocorticoid-Induced Osteoporosis. *Calcif Tissue Int*, 2012, 91, s. 225–243.
  - 68 Rizzoli, R. – Reginster, J. Y. – Boonen, S., et al.: Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. *Calcif Tissue Int*, 2011, 89, s. 91–104.
  - 69 Rizzoli, R. – von Tscharner, V. – Fleisch, H.: Increase of adenylate cyclase catalytic-unit activity by dexamethasone in rat osteoblast-like cells. *Biochem J*, 1986, 237, s. 447–454.
  - 70 Rochefort, G. Y. – Pallu, S. – Benhamou, C. L.: Osteocyte: the unrecognized side of bone tissue. *Osteoporos Int*, 2010, 21, s. 1457–1469.
  - 71 Saag, K. G. – Emkey, R. – Schnitzer, T. J., et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. *N Engl J Med*, 1998, 339, s. 292–299.
  - 72 Saag, K. G. – Shane, E. – Boonen, S., et al.: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. *N Engl J Med*, 2007, 357, s. 2028–2039.
  - 73 Saag, K. G. – Zanchetta, J. R. – Devogelaer, J. P., et al.: Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. *Arthritis Rheum*, 2009, 60, s. 3346–3355.
  - 74 Sambrook, P. – Birmingham, J. – Kelly, P., et al.: Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. *N Engl J Med*, 1993, 328, s. 1747–1752.
  - 75 Sivagurunathan, S. – Muir, M. M. – Brennan, T. C., et al.: Influence of glucocorticoids on human osteoclast generation and activity. *J Bone Miner Res*, 2005, 20, s. 390–398.
  - 76 Steinbuch, M. – Youket, T. E. – Cohen, S.: Oral glucocorticoid use is associated with an increased risk of fracture. *Osteoporos Int*, 2004, 15, s. 323–328.
  - 77 Stoch, S. A. – Wagner, J. A.: Cathepsin K inhibitors: a novel target for osteoporosis therapy. *Clin Pharmacol Ther*, 2008, 83, s. 172–176.
  - 78 Ström, O. – Borgström, F. – Kanis, J. A., et al.: Osteoporosis: burden, health care provision and opportunities in the European Union. *Arch Osteoporos*, 2011, doi: 10.1007/s11657-011-0060-1.
  - 79 Adachi, J. D. – Bensen, W. G. – Brown, J., et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. *N Engl J Med*, 1997, 337, s. 382–387.
  - 80 Boutsen, Y., et al.: Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate a randomized trial. *Calcif Tissue Int*, 1997, 61, s. 266–271.
  - 81 Cohen, S., et al.: *J Bone Miner Res*, 1998, 23 (dopl. 5), s. S595.
  - 82 Devogelaer, J. P., et al.: *J Bone Miner Res*, 1998, 23 (dopl. 5), s. S480.
  - 83 Saag, K., et al.: *J Bone Miner Res*, 1998, 23 (dopl. 5), s. S182.
  - 84 Reid, D., et al.: *Arthritis Rheum*, 1998, 41, s. S136.
  - 85 Jin et al.: *J Biol Chem*, 2000, 35, s. 27238.
  - 86 Taylor, K. A.: Conference ISCD, 2007 (abstrakt 171).

# Novinky v diagnostice a léčbě spánkové apnoe

MUDr. Milada Hobzová, Ph.D. Klinika plicních nemocí a tuberkulózy LF UP a FN, Olomouc

- 1 Šonka, K., et al.: Apnoe a další poruchy dýchání ve spánku. Praha, Grada, 2004.
- 2 Nevšimalová, S. – Šonka, K., et al.: Poruchy spánku a bdění. Praha, Galén, 2007.
- 3 Šonka, K. – Slonková, J.: Spánková apnoe dospělého věku. *Cesk Slov Neurol N*, 2008, 71, s. 643–656.
- 4 Qaseem, A. – Dallas, P. – Owens, D. K., et al.: Diagnosis of obstructive sleep apnoea in adults: A clinical practice guideline from the American College of Physicians. *Ann Intern Med*, 2014, 161, s. 210–220.
- 5 Parati, G. – Lombardi, C. – Hedner, J., et al.: Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of the European COST (Cooperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. *J Hypertens*, 2012, 30, s. 633–646.
- 6 Bradley, T. G. – Floras, J. S.: Obstructive sleep apnoea and its cardiovascular consequences. *Lancet*, 2009, 373, s. 82–93.
- 7 McNicholas, W. T. – Bonsignore, M. R.: Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms, and research priorities. *Eur Respir J*, 2007, 29, s. 156–178.
- 8 Grote, L. – Sommermayer, D.: Early atherosclerosis and cardiovascular events. *Eur Respir Mon*, 2010, 50, s. 174–188.
- 9 Lavie, L. – Lavie, P.: Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. *Eur Respir J*, 2009, 33, s. 1467–1484.
- 10 Torres, G. – Sánchez-de-la-Torre, M. – Barbé, F.: Relationship between OSA and hypertension. *Chest*, 2015, 148, s. 824–832.
- 11 Young, T. – Palta, M. – Dempsey, J., et al.: The occurrence of sleep disordered breathing among middle aged adults. *N Engl J Med*, 1993, 328, s. 1230–1235.
- 12 Lindberg, E.: Epidemiology of OSA. In: *Eur Respir Mon* 50, Plymouth, European Respiratory Society, 2010, s. 51–68.
- 13 Ye, L. – Pien, G. W. – Weaver, T. E.: Gender differences in the clinical manifestation of obstructive sleep apnea. *Sleep Med*, 2009, 10, s. 1075–1084.
- 14 Johns, M. W.: A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. *Sleep*, 1991, 14, s. 540–545.
- 15 Parati, G. – Lombardi, C. – Hedner, J., et al.: Recommendations for the management of patients with obstructive sleep apnoea and hypertension. *Eur Respir J*, 2013, 41, s. 523–538.
- 16 Abrishami, A. – Khajehdehi, A. – Chung, F.: A systematic review of screening questionnaires for obstructive sleep apnea. *Can J Anaesth*, 2010, 57, s. 423–438.
- 17 Mallampati, S. R.: Clinical sign to predict difficult tracheal intubation (hypothesis). *Can Anaesth Soc J*, 1983, 30, s. 316–317.
- 18 Gaddam, K. – Pimenta, E. – Thomas, S. J.: Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. *J Hum Hypertens*, 2009, 24, s. 532–537.
- 19 Iftikhar, I. H. – Hays, E. R. – Iverson, M. A., et al.: Effect of oral appliances on blood pressure in obstructive sleep apnea: a systematic review and meta-analysis. *J Clin Sleep Med*, 2013, 9, s. 165–174.
- 20 Marklund, M. – Verbraecken, J. – Randerath, W.: Non-CPAP therapies in obstructive sleep apnoea: mandibular advancement device therapy. *Eur Respir J*, 2012, 39, s. 1241–1247.
- 21 Van Maanen, J. P. – de Vries, N.: Long-term effectiveness and compliance of positional therapy with the sleep position trainer in the treatment of positional obstructive sleep apnoea syndrome. *Sleep*, 2014, 37, s. 1209–1215.
- 22 Kezirian, E. J. – Goding, G. S. – Malhotra, A., et al.: Hypoglossal nerve stimulation improves obstructive sleep apnea: 12-month outcomes. *J Sleep Res*, 2014, 23, s. 77–83.
- 23 Klozar, J.: Jak odstranit chrápání? *Interní Med*, 2011, 13, s. 51–53.
- 24 Sullivan, C. E. – Berthon-Jones, M. – Issa, F. G., et al.: Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nose. *Lancet*, 1981, 1, s. 862–865.

## Přístup k diagnostice teplot nejasného původu a „laterální myšlení“

MUDr. Luboš Kotík, CSc. I. interní oddělení, Fakultní Thomayerova nemocnice, Praha

- 1 Arnow, P. M. – Flaherty, J. P.: Fever of unknown origin. *Lancet*, 1997, 350, s. 575–580.
- 2 Durack, D. T. – Street, A. C.: Fever of unknown origin reexamined and redefined. *Curr Clin Topics in Infect Dis*, 1991, 11, s. 35–51.
- 3 Knockaert, D. C. – Dujardin, K. S. – Bobbaers, J.: Long term follow-up of patients with undiagnosed fever of unknown origin. *Arch Intern Med*, 1996, 156, s. 616–620.
- 4 Knockaert, D. C. – Vanderschueren, S. – Blockmans, D.: Fever of unknown origin in adults: 40 years on. *J of Internal Medicine*, 2003, 253, s. 263–275.

## Dětská myopie na postupu

prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 Dolgin, E.: The myopia boom. *Nature*, 2015, 519, s. 276–278.
- 2 Morgan, I. G. – Ohno-Matsui, K. – Saw, S. M.: Myopia. *The Lancet*, 2012, 379, s. 1739–1748.
- 3 Morgan, I. – Rose, K.: How genetic is school myopia? *Progress in Retinal and Eye Research*, 2005, 24, s. 1–38.
- 4 Wojciechowski, R.: Nature and nurture: The complex genetics of myopia and refractive error. *Clinical Genetics*, 2011, 79, s. 301–320.
- 5 Hobday, R.: Myopia and daylight in schools: a neglected aspect of public health? *Perspectives in Public Health*, publikováno před tiskem, 2015.
- 6 Strong, E. M.: Proper school lighting. *American Journal of Public Health*, 1956, 46, s. 610–622.
- 7 Sorsby, A.: *Refraction and its components in twins*. Privy Council. Medical Research Council Special report no. 303, 1962. Londýn, HMSO.
- 8 Lyhne, N. – Sjølie, A. K. – Kyvik, K. O. – Green, A.: The importance of genes and environment for ocular refraction and its determiners: A population based study among 20–45 year old twins. *British Journal of Ophthalmology*, 2001, 85, s. 1470–1476.
- 9 Does Homework Perpetuate Inequities in Education? *PISA in Focus*, 2014, 46, s. 4, OECD.
- 10 Jones, L. A. – Sinnott, L. T. – Mutti, D. O. – Mitchell, G. L., et al.: Parental history of myopia, sports and outdoor activities, and future myopia. *Investigative Ophthalmology and Visual Science*, 2007, 48, s. 3524–3532.
- 11 Rose, K. A. – Morgan, I. G. – Ip, J., et al.: Outdoor activity reduces the prevalence of myopia in children. *Ophthalmology*, 2008, 115, s. 1279–1285.
- 12 Alvarez, A. A. – Wildsoet, C. F.: Quantifying light exposure patterns in young adult students. *Journal of Modern Optics*, 2013, 60, s. 1200–1208.
- 13 Ashby, R. – Ohlendorf, A. – Schaeffel, F.: The effect of ambient illuminance on the development of deprivation myopia in chicks. *Investigative Ophthalmology and Visual Science*, 2009, 50, s. 5348–5354.
- 14 Siegart, J. T. – Ward, A. H. – Norton, T. T.: Moderately elevated fluorescent light levels slow form deprivation and minus lens-induced myopia development in tree shrews. *Investigative Ophthalmology & Visual Science*, 2012, 53, s. 3457.
- 15 Smith, E. L. – Hung, L. F. – Juany, J.: Protective effects of high ambient lighting on the development of form-deprivation myopia in rhesus monkeys. *Investigative Ophthalmology and Visual Science*, 2012, 53, s. 421–428.
- 16 Moinul, P. – Cheng, E. – Stell, W.: Nitric oxide prevents form-deprivation myopia in chicks without requiring a dopamine D2-receptor relay. *Investigative Ophthalmology & Visual Science*, 2012, 53, s. 3434.
- 17 Start, C. – Mangel, S. C.: The circadian clock in the mammalian retina uses dopamine and melatonin receptor activation to control rod and cone input to ganglion cells. *Investigative Ophthalmology & Visual Science*, 2011, 52, s. 5281.